© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Nimustine hydrochloride saw its roots in cancer research during the late twentieth century. Chemists working through the hurdles of drug resistance in brain tumors wanted a compound that delivered both potency and better penetration into the central nervous system. Out of this challenge, Japanese pharmaceutical teams led the charge. They synthesized nimustine, recognizing its potential to cross the blood-brain barrier and target deeply embedded malignancies. What started in a handful of academic laboratories grew into a treatment option defined by rigorous clinical trials and regulatory scrutiny, reflecting both scientific persistence and the ever-present hope of oncology research.
Nimustine hydrochloride belongs to the nitrosourea class of alkylating agents. As a fine, off-white crystalline powder, it often comes sealed within vials, reserved strictly for injection after careful reconstitution. Unlike more familiar drugs that frequently surface in general chemotherapy, nimustine found its way into especially tough cancers, most often certain types of brain tumors and lymphomas. The appeal has always come down to its effectiveness where other chemotherapeutics fell short, which explains why hospitals consider it for those complex cancer cases with few other alternatives.
Looking at it in a lab, nimustine hydrochloride reveals a modest molecular weight and a chemical structure marked by a nitrosourea group bonded to a chlorinated aromatic ring. The powder dissolves fairly readily in water and some organic solvents, making it manageable for clinical preparation. Its melting point stands relatively low for a pharmaceutical ingredient, which demands careful, controlled storage under refrigeration to stave off decomposition. The compound doesn’t stick much to glass or plastic, simplifying handling in pharmacy settings. Its molecular design carries a potent ability to cause cross-linking in DNA, which sits at the center of its anti-cancer action but also triggers a set of tricky safety issues.
Manufacturers deliver nimustine hydrochloride with specific content requirements—purity typically sits above 98%, and moisture levels stay under tight watch to avoid degradation. Each package or vial holds labeling that lays out concentration, storage requirements, route of administration, and critical precautions such as dosing adjustments. Hazard codes reflect the drug’s cytotoxic nature, signaling pharmacy teams and clinicians alike to handle the product with robust personal protective gear. Clear batch and expiry tracking tie in, matching today’s push for increased transparency and traceability in drug delivery.
Lab synthesis of nimustine hydrochloride draws from the chemical route of difunctionalizing a nitrosourea backbone. Fluids, glassware, and reagents demand extra scrutiny since impurities or excess moisture can trigger unwanted side products. Chlorination, nitrosation, and careful neutralization mark the main steps. Each stage gets assessed by thin-layer or high-performance liquid chromatography—no one wants leftover raw materials creeping into the finished product. Once synthesized, conversion to the hydrochloride salt locks in stability, after which the compound undergoes a round of purification before shipping out to medical facilities.
The functional nitrosourea group is nimustine’s signature. It reacts with nucleophilic centers in DNA, leading to crosslinks that interrupt cell division. In research labs, chemists experimented with site-specific modifications—sometimes swapping pieces of the aromatic ring, other times tinkering with the length of the alkyl groups. These changes sought to adjust how nimustine interacts with cell membranes or its overall toxicity profile. For all that tweaking, most attempts stuck close to the initial structure, since over-alteration can wipe out its anti-cancer edge. Modifiers tread carefully; even seemingly minor changes can shift potency or trigger unexpected side effects.
Nimustine hydrochloride has gone by several trade names, most commonly ACNU, in clinical circles. Synonyms appearing across research papers include nimustine, ACNU hydrochloride, and its full chemical name: 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea hydrochloride. While regional manufacturers may stamp their own trade names, the structure and application remain the same. These synonyms help link the growing archive of real-world studies, product inserts, and regulatory alerts, easing the efforts of clinicians looking up data from varied international sources.
In any hospital pharmacy, nimustine hydrochloride prompts a distinct set of precautions. Staff work in biological safety cabinets, employ double gloves, and use closed-system transfer devices for preparation. Direct skin contact risks both acute toxicity and cumulative adverse health effects, while powder or solution spills have triggered institutional reviews before. Ongoing staff training and waste disposal protocols have become routine, with monitoring for accidental exposure written into many oncology centers’ best practices. Regulatory agencies like the FDA and EMA mapped clear packaging and labeling requirements, reinforcing a culture of caution linked to these potent chemotherapeutics.
Nimustine hydrochloride remains central in the treatment of primary brain tumors such as glioblastoma multiforme and certain relapsed or refractory lymphomas. Its ability to cross the blood-brain barrier gives it an edge where other agents falter. Some regional protocols also explore its use for other solid tumors, pairing it with radiation or additional drugs to maximize cancer cell kill. In resource-constrained programs, nimustine can find a place in salvage therapy, after first and second-line regimens have failed. The narrow window between effective dose and severe adverse reactions demands a strong hand guiding administration and monitoring, which limits use almost entirely to specialty cancer centers.
Academic and pharmaceutical teams continue to put nimustine hydrochloride under the microscope. Studies investigate optimal dosing schedules and look for biomarker profiles to identify which patients stand to benefit most from its action. Researchers hunt for ways to blunt resistance, often by pairing nimustine with new or repurposed agents. Clinical trial data surface across peer-reviewed journals, especially out of Asia where experience with the drug runs deepest. Genetic sequencing tools and digital pathology open up fresh avenues to understand why some tumors crumble and others bear down under the same treatment. Broader international registries help track outcomes beyond limited, single-institution studies.
Clinicians learned quickly that nimustine brings real risks, especially at higher cumulative doses. Myelosuppression stands out as the leading concern, limiting repeated cycles and demanding close blood monitoring. Pulmonary toxicity can surface with delayed symptoms, making long-term surveillance a must. Animal studies flagged neurotoxicity at higher concentrations, and real-world experience echoes those findings in sensitive patient groups. Combined drug protocols can magnify toxicity, so clinicians often weigh the tradeoffs case by case. Ongoing research chases less harmful analogs, but so far every solution comes with its own baggage of unwanted effects.
People fighting brain tumors and certain relapsed cancers rely on nimustine hydrochloride as part of their toolkit. Drug developers and oncologists keep searching for ways to extend benefits without tipping over into serious harm. Advances in drug delivery—like using liposomal carriers or local implants—spark new hope for reducing side effects while raising tissue concentrations where it counts. Biomarker-driven deployment may pull nimustine into a more personalized medicine world, moving away from one-size-fits-all protocols. International collaboration, stronger post-marketing surveillance, and continued learning from patient registries shape the path ahead. As drug resistance keeps challenging the oncology field, chemistry and medicine will likely keep circling back to nimustine’s lessons and its still unfolding story.
Nimustine Hydrochloride serves as a chemotherapy agent, mostly used in hospitals across Asia and Europe. Many doctors reach for it when fighting tough brain tumors like gliomas or cancers such as lymphoma. Nimustine belongs to a family of drugs called nitrosoureas, which are known for their ability to cross the blood-brain barrier. This feature means the medicine can reach cancer cells hiding deep in the brain where most drugs struggle to penetrate.
Anyone watching a loved one battle brain cancer understands why finding something that can reach those hidden cells counts for so much. Traditional chemotherapy often gets blocked by the body’s own natural guards, leaving difficult cancers to grow unchecked. A drug like nimustine brings hope because it gives oncologists another tool in an area where options usually run thin.
Using nimustine isn’t just about targeting hard-to-reach spots. Research from Japanese clinical trials highlights its contribution to longer survival rates in certain brain tumor patients. The drug interferes with the DNA inside cancer cells, making it nearly impossible for them to multiply and spread. By attacking the cancer at the genetic level, nimustine slows—and sometimes stops—the disease’s progress.
Like most chemotherapy medicines, nimustine doesn’t arrive without side effects. Doctors watch for lowered immunity, upset stomach, lowered blood counts, and, at times, kidney issues. My own uncle went through months of chemotherapy for a brain tumor. He faced nausea, lost weight, but still said he’d take the trade-off because nothing else gave his medical team much of a fighting chance.
Doctors try to balance effective treatment with a lower risk of harm. Nimustine often comes into play when the possibilities have narrowed. It sometimes joins with other drugs or radiation, building a stronger defense against aggressive tumors.
Nimustine Hydrochloride doesn’t appear in every hospital pharmacy. In places like Japan, it stands as a regular part of cancer care. Elsewhere, doctors can face hurdles just getting it approved for use. Price can limit access. Approval bottlenecks and lack of familiarity among some medical communities sometimes leave patients waiting for something better or traveling far for a chance at this medicine.
Experts push for more studies, especially outside Asia, to give patients broader access and better outcomes. The World Health Organization and leading cancer centers track these efforts, recognizing that treatments crossing into new territories often face layers of skepticism, along with high standards meant to protect patient safety.
Innovation rarely arrives in a straight line. Nimustine emerged after researchers demanded more for patients whose cancers showed no mercy. It didn’t replace other treatments, but it made a real difference for a specific group of people. My experience tells me that most progress in medicine happens this way. Doctors and scientists learn, adapt, and look for new combinations to tip the odds.
Ongoing patient monitoring tells health professionals where nimustine delivers the most value. Community discussions matter as real families look for answers, share their journeys, and support each other while navigating the risks and hopes behind every prescription the doctor writes.
Nimustine Hydrochloride shows up in hospitals as a chemotherapy drug. Doctors use it mainly against brain tumors, lymphomas, and lung cancer. Its promise to fight cancer cells often comes with some tough side effects. As someone who’s watched a loved one go through cancer treatment, I’ve seen what these drugs can do—not just to the illness, but to the rest of the body.
During treatment, the most common problem is a drop in white blood cells. Chemotherapy doesn’t only attack cancer—it goes after healthy, fast-growing cells too. Low white blood cells mean the body can’t fend off infections as easily. Even a mild fever can turn serious; patients often get told to call their doctor at the first sign of a cough or cold.
Low platelets also show up in lab tests. That means bruising and bleeding can happen more easily. I still remember my uncle explaining how even a soft bump on the arm left a big, purple mark. Nurses would gently remind him to steer clear of sharp objects and keep an eye on bleeding gums after brushing his teeth.
Fatigue gets people too. Chemotherapy brings a tiredness that sleep doesn't erase. On bad weeks, people might spend most of the day in bed, their muscles aching and their minds fuzzy. Appetite often fades, and weight loss creeps in. People who once loved a good meal start picking at food, turning away from strong smells, or just skipping lunch because nothing sounds good.
Nimustine can also damage organs over time. The liver and kidneys break down chemotherapy drugs, which puts them under stress. Blood tests track liver numbers and kidney function at each visit, but sometimes problems build anyway. Liver damage might show up in yellowing skin, dark urine, or stomach pain. Kidneys work harder to filter waste. When they struggle, swelling in the ankles or changes in urination can follow.
There’s also a heightened risk of future cancers. Chemotherapy can change how our genes work, and that could lead to another cancer years down the road. It’s a tough reality for anyone fighting a disease in the present, knowing the treatment could cause trouble years later.
Open communication matters most. Too many patients keep quiet about their symptoms, thinking they should just put up with them. No one wins that way. Oncology teams can adjust doses or offer extra medications to boost white cell counts or manage nausea, but only if they know what’s happening at home.
Nutrition also makes a difference. Dietitians help patients find foods that suit their new tastes or go easy on irritated stomachs. Small, frequent meals work better for some people. Hydration becomes critical—and not just with water. Broths, smoothies, or electrolyte drinks keep patients hydrated and energized.
Family and mental health support matter as much as the medication itself. Talking to social workers or counselors can help patients deal with anxiety, frustration, or depression as they cope with side effects and the stress of cancer. Support groups connect people facing the same struggles and let them exchange advice on how to get through the hardest days.
Nimustine Hydrochloride does what it’s designed to do: it gives some cancer patients more time. That time means more appointments, blood draws, and rough days. By focusing on side effects, supporting nutrition and mental health, and keeping healthcare conversations honest, we help people hold on to quality of life—not just survival.
I remember some of my early days shadowing oncology teams, watching big bags of clear or slightly yellow fluids hanging above patients. Those infusions carried stories, hope, and heavy chemistry. Nimustine Hydrochloride sits among those chemotherapy agents. It’s not a pill one swallows at home or something you grab from the local pharmacy. Its administration has a serious clinical choreography.
Doctors rely on intravenous infusion to give nimustine hydrochloride. That means a nurse or physician mixes the drug in a sterile solution, often saline or glucose, inside a hospital or clinic under a specialist’s care. The dose depends on the patient’s height, weight, kidney and liver function, and the type of cancer. Lung cancer, brain tumors, and certain lymphomas come up most often in medical literature and treatment guidelines.
Hospital pharmacies keep strict records for a reason: Nimustine’s handling raises safety concerns. Oncologists and pharmacists wear gloves, masks, and goggles. One reason comes down to the drug’s toxicity profile—exposure is not safe even for those preparing the medicines.
Before an IV gets inserted, patients hear warnings about possible side effects. Myelosuppression—depressed bone marrow activity—shows up commonly, so blood counts receive close monitoring before and after. I’ve seen experienced nurses check lab results, crack jokes to ease tension, and keep their eyes sharp for reactions. It’s a rapport that builds trust.
Unlike swallowing a pill, a nimustine infusion takes time. Patients lie in recliners, sometimes with a family member holding their hand as “the drip” enters a vein slowly over minutes to an hour, depending on dose and tolerance. People talk about a metallic taste, sometimes nausea, fatigue, or chills coming on during or after it finishes. Those days are not easy. Hospital visits disrupt routines. Travel, work, childcare, all reshuffle around cancer appointments.
There’s risk of extravasation—where the medicine leaks out of the vein into surrounding tissue—which creates pain and complications if not addressed early. Nurses watch carefully. The human touch here isn’t a luxury, it’s a necessity.
The choice to use intravenous infusion isn’t random. Oral drugs get digested and filtered by the gut and liver before reaching the rest of the body. With aggressive tumors, you want a direct route. Infusion sends nimustine coursing through the bloodstream, reaching the cancer site with more predictable concentrations.
Protocols come down to safety, consistency, and clarity over every step. Problems like kidney or liver disease may trigger dose changes or extra hydration, aiming to lower toxicity but still attack the cancer hard.
Cancer never waits. The more I learn, the more I see that improvements in how drugs like nimustine hydrochloride are given really do save lives and protect staff. Hospitals now invest in closed-system transfer devices and regular safety training. Reports in reputable journals—from the Journal of Clinical Oncology to regional bulletins—keep pointing out that workflow, thorough patient education, and supporting oncology nurses contribute to fewer complications and better patient experiences.
In the end, nimustine hydrochloride’s administration isn’t just a technical act—it’s part of a relationship, a promise to do no harm while fighting disease. That’s not just science; it’s real care.
Cancer treatment rarely comes with a one-size-fits-all approach. Nimustine Hydrochloride, which doctors often use to treat brain tumors and certain cancers, requires careful dosing. That’s not something anyone wants to gamble with. Sitting in a hospital room with someone going through chemotherapy, I’ve watched oncologists calculate every milligram based on patient-specific factors, and it drives home why individual recommendations change so much.
Unlike over-the-counter medicines, anticancer drugs need personalized adjustments. For Nimustine Hydrochloride, typical starting doses for adults often fall around 100 mg to 150 mg per square meter, given as an intravenous infusion, but that can drop or rise depending on a person’s kidney and liver function, age, and the status of their immune system. Adverse effects like bone marrow suppression aren’t just possibilities; they’re real risks, so doctors check blood counts often. Even one round of chemotherapy puts this into perspective—the hospital’s pharmacy weighs and mixes the powder while nurses chart every stage of the process.
Many oncologists recommend repeating the drug every 6 to 8 weeks, but that interval might shift if the patient’s marrow can’t recover quickly enough. This is not a decision taken lightly; I’ve seen therapy interrupted or reduced because a patient's platelets dropped too low, setting off concerns about bleeding and infection. Some patients need support transfusions or growth factors, and families sit in the waiting room with new worries each time.
A patient’s weight and height can affect drug calculations, but the story grows more complicated. Elderly and frail people often can’t handle what younger, healthier adults might finish. Japanese prescribing information offers some of the tightest guidelines, suggesting maximum single doses and strict conditions for re-dosing. In practice, people with low white blood cell counts won’t see another dose until lab numbers improve.
Kidneys and Liver: The Unsung HeroesNimustine Hydrochloride breaks down in the body mainly through the liver. So, anyone with liver problems faces more risk. Doctors run liver and kidney tests before each dose, because skipping this step could put people in harm’s way. If lab results look bad, the doctor might drop the dose or hold off treatment. Years ago, I saw a patient’s recovery slow to a crawl after missing one of these checks; the lesson stayed with me.
Clear, frequent communication matters. Patients often ask if they should prepare differently for each cycle. From my experience, jotting down how you feel each day and sharing side effects with your oncologist allows for earlier actions—sometimes lowering the dose, spacing treatments, or offering extra medicines to help cope. As someone who's watched family members navigate this, I can say those conversations reduce stress and keep therapy on track.
Access to Reliable Sources of InformationModern research, including studies published in journals like the International Journal of Clinical Oncology and guidelines from trusted cancer centers, help patients and caregivers understand safety nets. The World Health Organization and local regulatory bodies issue clear, fact-driven dose recommendations based on large trials and decades of data, grounding the process in real evidence.
People deserve individualized care. If you’re starting treatment, it helps to remember your oncologist navigates a complex balancing act. Honest conversations, thorough monitoring, and a willingness to adjust each dose can mean fewer complications and a better shot at feeling well through every step of treatment.
Nimustine hydrochloride plays a role in treating certain cancers, especially brain tumors. The drug blocks DNA repair and slows the growth of cancer cells. Doctors appreciate its power, but no medicine like this comes risk-free. I remember watching a friend struggle with chemotherapy. Each treatment brought fear and uncertainty, not just about the cancer but about what the drug added to the mix.
Nimustine isn’t a choice for everyone. People with poor bone marrow function sit on shaky ground. This drug can slam down hard on blood cell counts, raising infection risk or triggering bleeding. Before giving nimustine, doctors usually run blood tests. If results show low platelets, white cells, or red cells, nimustine can push the situation into dangerous territory. I’ve seen patients who ignored an early infection warning sign spend weeks fighting off sepsis after an immune drop caused by chemo.
Those who deal with kidney or liver problems face extra danger, too. The body clears nimustine using these organs. My aunt once took cancer meds without knowing her liver was struggling—the toxic build-up made her sicker than the disease. Doctors watch liver and kidney numbers here for good reason.
Nimustine can also spark allergic reactions. Some people break out in rashes or have trouble breathing not long after treatment begins. It’s rare, but in emergency rooms, I’ve seen how quickly a simple allergy can tip into life-threatening shock.
Many people treat cancer while juggling other conditions. Nimustine doesn’t mix well with a long list of drugs, particularly those that thin blood or suppress the immune system. Aspirin and warfarin, for instance, make bleeding problems worse. Even certain antibiotics can tangle with nimustine’s effects. Not long ago, a family friend’s chemotherapy clashed with blood pressure pills, setting off days of confusion and side effects that doctors had to pull apart medication by medication.
Pregnant women or those planning a family face tough choices here. Nimustine can harm developing babies. Studies in animals show birth defects and long-term problems. I’ve heard too many stories of heartbreak in oncology waiting rooms from women who weren’t told about the dangers early enough. Reliable birth control becomes a must during and after therapy for both men and women.
Doctors and nurses can make a big difference by talking openly about these risks. Patients crave straight talk—not medical jargon—on what to look for, what to avoid, and what numbers count on lab reports. My experience has shown that sitting down for a direct conversation about chemo side effects beats a handout every time.
Everyone working with nimustine should run blood work and organ checks both before and during therapy. Doctors also have to check drug lists for anything that might clash. Pharmacies can use smart systems to flag risky combos. Families need to feel ready to call for help at the first sign of fever, rash, or easy bruising—not wait until a scheduled visit. By paying attention and acting fast, many complications can be caught early. Good care with nimustine starts with vigilance, respect for the drug’s power, and open, ongoing conversations between patients and their teams.
| Names | |
| Preferred IUPAC name | (1-methyl-1-nitrosourea)-N-(2-chloroethyl)-N'-[(4-methylcyclohexyl)carbonyl]hydrazinium chloride |
| Other names |
ACNU Nimustine Nimustin Nimustinum hydrochloricum |
| Pronunciation | /naɪˈmʌsˌtin haɪˌdrɒklaɪd/ |
| Identifiers | |
| CAS Number | [“38955-32-5”] |
| 3D model (JSmol) | `3D model (JSmol)` string for **Nimustine Hydrochloride**: ``` ClCCN(CCCl)C(=O)Nc1cccc2c1nc(no2)N.Cl ``` |
| Beilstein Reference | 2733351 |
| ChEBI | CHEBI:7516 |
| ChEMBL | CHEMBL1781053 |
| ChemSpider | 20295785 |
| DrugBank | DB11742 |
| ECHA InfoCard | 100.112.455 |
| EC Number | 2924-52-5 |
| Gmelin Reference | 64167 |
| KEGG | D01897 |
| MeSH | D017961 |
| PubChem CID | 3034427 |
| RTECS number | KH8561000 |
| UNII | 2DC7WGH3ZG |
| UN number | UN1851 |
| Properties | |
| Chemical formula | C9H13ClN4O2 |
| Molar mass | 367.78 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.7 g/cm3 |
| Solubility in water | Soluble in water |
| log P | 0.94 |
| Acidity (pKa) | 13.07 |
| Basicity (pKb) | 1.78 |
| Magnetic susceptibility (χ) | -65.0e-6 cm³/mol |
| Dipole moment | 3.55 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Nimustine Hydrochloride: 568.5 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | L01AD03 |
| Hazards | |
| Main hazards | Toxic if swallowed. Causes serious eye irritation. May cause genetic defects. May cause cancer. |
| GHS labelling | GHS02, GHS06, GHS08 |
| Pictograms | GHS06, GHS08 |
| Signal word | Danger |
| Hazard statements | H300 + H310 + H330: Fatal if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | Handle under strict supervision. Use personal protective equipment. Avoid contact with skin and eyes. Do not breathe dust or vapors. Work in a well-ventilated area or fume hood. Dispose of contents/container in accordance with local regulations. |
| Lethal dose or concentration | LD50 (mouse, intravenous): 10 mg/kg |
| LD50 (median dose) | LD50 (median dose): 61 mg/kg (i.v., mouse) |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 100 mg |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Carmustine Lomustine Semustine Chloroethyl nitrosourea |
